TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials

BACKGROUND: Time to progression (TTP) is suggested as a reliable endpoint compared with the progression-free survival in the clinical trials of hepatocellular carcinoma (HCC). However, the correlation between TTP and overall survival (OS) has never been studied. METHODS: We searched PubMed and Embas...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dae-Won, Jang, Myoung-Jin, Lee, Kyung-Hun, Cho, Eun Ju, Lee, Jeong-Hoon, Yu, Su Jong, Kim, Yoon Jun, Yoon, Jung-Hwan, Kim, Tae-Yong, Han, Sae-Won, Oh, Do-Youn, Im, Seock-Ah, Kim, Tae-You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104893/
https://www.ncbi.nlm.nih.gov/pubmed/27736843
http://dx.doi.org/10.1038/bjc.2016.322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104893/
https://www.ncbi.nlm.nih.gov/pubmed/27736843
http://dx.doi.org/10.1038/bjc.2016.322

Ejemplares similares